These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27902970)

  • 1. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.
    Lohse I; Mason J; Cao PM; Pintilie M; Bray M; Hedley DW
    Oncotarget; 2017 Jan; 8(2):3064-3071. PubMed ID: 27902970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
    Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X
    Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.
    Mason JM; Lin DC; Wei X; Che Y; Yao Y; Kiarash R; Cescon DW; Fletcher GC; Awrey DE; Bray MR; Pan G; Mak TW
    Cancer Cell; 2014 Aug; 26(2):163-76. PubMed ID: 25043604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
    Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
    Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1913-1918. PubMed ID: 29434041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
    Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
    Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
    Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
    Sredni ST; Suzuki M; Yang JP; Topczewski J; Bailey AW; Gokirmak T; Gross JN; de Andrade A; Kondo A; Piper DR; Tomita T
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28398638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
    Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
    Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polo-like kinase 4 inhibition: a strategy for cancer therapy?
    Holland AJ; Cleveland DW
    Cancer Cell; 2014 Aug; 26(2):151-3. PubMed ID: 25117704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
    Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
    J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer.
    Suri A; Bailey AW; Tavares MT; Gunosewoyo H; Dyer CP; Grupenmacher AT; Piper DR; Horton RA; Tomita T; Kozikowski AP; Roy SM; Sredni ST
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma.
    Lee HHY; Chow KL; Wong HS; Chong TY; Wong AST; Cheng GHW; Ko JMK; Siu HC; Yeung MCF; Huen MSY; Tse KY; Bray MR; Mak TW; Leung SY; Ip PPC
    Clin Cancer Res; 2024 Sep; 30(17):3904-3918. PubMed ID: 38848043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer.
    Parsyan A; Cruickshank J; Hodgson K; Wakeham D; Pellizzari S; Bhat V; Cescon DW
    Breast; 2021 Aug; 58():6-9. PubMed ID: 33866248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLK4: a link between centriole biogenesis and cancer.
    Maniswami RR; Prashanth S; Karanth AV; Koushik S; Govindaraj H; Mullangi R; Rajagopal S; Jegatheesan SK
    Expert Opin Ther Targets; 2018 Jan; 22(1):59-73. PubMed ID: 29171762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLK4: a promising target for cancer therapy.
    Zhao Y; Wang X
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2413-2422. PubMed ID: 31492983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A PLK4 inhibitor has single-agent activity in preclinical tumor models.
    Cancer Discov; 2014 Sep; 4(9):OF11. PubMed ID: 25185193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of targeting polo-like kinase 4.
    Lei Q; Yu Q; Yang N; Xiao Z; Song C; Zhang R; Yang S; Liu Z; Deng H
    Eur J Med Chem; 2024 Feb; 265():116115. PubMed ID: 38199166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells.
    Kerschner-Morales SL; Kühne M; Becker S; Beck JF; Sonnemann J
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2871-2883. PubMed ID: 32770382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
    Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
    Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.